Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

348
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
348
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.6K
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

79
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
79
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

127
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
127
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.7K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

156
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Entropy-Driven Nucleic Acid Amplifier Based on Spatial Confinement as a "Booster" for Detection of Extracellular Vesicle MicroRNAs to Diagnose Gastric Cancer and Monitor Therapeutic Response.

Analytical chemistry·2025
Same author

Evaluation of demographic factors affecting predictability of the sacro-femoral-pubic angle in healthy adolescents.

Journal of anatomy·2014
Same author

Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells.

Cancer letters·2014
Same author

[Association between -1296T/C and -915A/G polymorphisms of matrix metalloproteinase inhibitor-3 gene and atherosclerotic cerebral infarction in an ethnic Han Chinese population].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics·2014
Same author

A preliminary study on surgery for hepatocellular carcinoma patients with portal hypertension.

American journal of surgery·2014
Same author

[Development of CBCT technique and its application on dental age assessment].

Fa yi xue za zhi·2014

Related Experiment Video

Updated: May 13, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

27.6K

MDIPID: Microbiota-drug interaction and disease phenotype interrelation database.

Jiayi Yin1, Hui Ma1, Yuting Qi1,2

  • 1Department of Clinical Pharmacy, The First Affiliated Hospital Zhejiang University School of Medicine, Zhejiang University Hangzhou China.

Imeta
|April 16, 2025
PubMed
Summary

A new database, MDIPID, maps interactions between microbiota, microbial proteins, drugs, and diseases. This resource aids in identifying microbial therapy targets and advancing personalized medicine.

More Related Videos

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

12.8K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Related Experiment Videos

Last Updated: May 13, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

27.6K
Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
08:33

Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment

Published on: November 17, 2018

12.8K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Area of Science:

  • Microbiology
  • Pharmacology
  • Bioinformatics
  • Genomics
  • Systems Biology

Background:

  • Bidirectional relationships among microbiota, microbial proteins, drugs, and diseases are crucial for precision medicine and reducing adverse drug reactions.
  • Existing data resources do not comprehensively capture these complex interactions.
  • Understanding these interrelations is vital for developing targeted therapies and personalized treatment strategies.

Purpose of the Study:

  • To develop a comprehensive data resource, the Microbiota-Drug Interaction and Disease Phenotype Interrelation Database (MDIPID).
  • To elucidate the complex interactions among microbiota, microbial proteins, drugs/substances, and disease phenotypes.
  • To provide an interconnected network for identifying microbial therapy targets and advancing personalized medicine.

Main Methods:

  • Database development integrating data on microbiota, microbial proteins, drugs, and disease phenotypes.
  • Network construction to visualize and analyze interrelations.
  • Data curation and validation for accuracy and comprehensiveness.

Main Results:

  • Establishment of the Microbiota-Drug Interaction and Disease Phenotype Interrelation Database (MDIPID).
  • MDIPID provides a unique, interconnected network of microbiota, microbial proteins, drugs, and disease phenotypes.
  • The database facilitates the identification of potential microbial therapy targets.

Conclusions:

  • MDIPID is a valuable, freely accessible resource for researchers.
  • The database supports the identification of microbial therapeutic targets, drug efficacy prediction, and new therapy development.
  • MDIPID is expected to significantly advance personalized medicine and reduce adverse drug reactions.